Strategies & Technologies Driving Drug Discovery to Market
Subscribe to Drug Discovery & Development All
View Sample

FREE Email Newsletter

DDD Update

Daily news and top headlines for drug research professionals

J & J Grilled Over Secret Recall

September 22, 2010 8:12 am | by Matthew Perrone | News | Comments

Scrutiny of drug and consumer product giant Johnson & Johnson ratcheted up as a congressional chairman demanded the company provide proof of its claim that federal regulators cleared a plan to secretly buy up defective painkillers.


Justice Department Joins Wyeth Lawsuit

September 22, 2010 8:06 am | by Maryclaire Dale | News | Comments

The Justice Department has joined a whistleblower lawsuit that accuses Wyeth Pharmaceuticals of promoting the off-label use of a transplant drug in high-risk black patients, children and others.


Australian Regulators Approve Merck MS Drug

September 22, 2010 7:55 am | News | Comments

Merck KGaA announced that the Australian Therapeutic Goods Administration has approved Cladribine Tablets for the treatment of relapsing-remitting multiple sclerosis.


Cempra Taking Dual Approach to New Antibiotic

September 22, 2010 7:52 am | News | Comments

Cempra Pharmaceuticals announced that it is moving forward in its dual approach to the development of solithromycin (CEM-101), a fluoroketolide which is first of a new generation of macrolide-ketolide antibiotics for treatment of community-acquired bacterial pneumonia.


GSK Refocusing Ofatumumab for Autoimmune Disease

September 22, 2010 7:35 am | News | Comments

GSK and Genmab announced plans to refocus the development program of ofatumumab in autoimmune indications. After review of the program’s full development strategy, GSK will focus development efforts on the subcutaneous delivery of ofatumumab in autoimmune indications .


Myrexis Reports Preclinical Cancer Data

September 22, 2010 7:28 am | News | Comments

Myrexis, Inc., a biotechnology company focused on discovering, developing, and commercializing novel treatments for cancer, announced key findings from preclinical studies of the company's novel cancer metabolism inhibitor, MPC-9528.


Prostate Cancer Drug Performs Well in Phase 2a Study

September 22, 2010 7:22 am | News | Comments

Hybrigenics announced positive outcomes of a clinical tolerance Phase 2a study of daily oral inecalcitol in combination with gold standard Taxotere chemotherapy in hormone-refractory prostate cancer patients.


Micromet Starts Phase 2 Leukemia Trial

September 22, 2010 7:16 am | News | Comments

Micromet, Inc. announced the initiation of a phase 2 trial of the company's lead product candidate blinatumomab in adult patients with relapsed or refractory B-precursor acute lymphoblastic leukemia.


Novartis MS Drug Approved By FDA

September 22, 2010 7:13 am | by Matthew Perrone | News | Comments

Federal health regulators have approved the first pill to treat the underlying causes of multiple sclerosis, a debilitating nervous system disorder that has traditionally been treated with injectable drugs.


Laboratory Glassware

September 21, 2010 9:03 am | Product Releases | Comments

Kimble Chase introduces KimCote plastic coated glassware. KimCote is an ultra-clear coating that is applied to the exterior of laboratory glassware in order to resist breakage and contain leakage.


Protein Assay

September 21, 2010 8:57 am | Product Releases | Comments

CB-X Protein Assay is designed to be compatible with all commonly used buffers and reagents and therefore eliminates all concerns about selecting a protein assay that is compatible with a specific protein sample, buffer, or solubilization reagents.


IDT Expanding Vaccine Capacity

September 21, 2010 8:53 am | News | Comments

IDT Biologika GmbH, a global integrated contract manufacturer of vaccines and biopharmaceuticals, introduced plans to expand its viral vaccine production capacity with the addition of a new high-speed filling line and additional lyophilisation capacity.


FDA Panel Backs VIVITROL For Opioid Addiction

September 21, 2010 8:50 am | News | Comments

Alkermes, Inc. announced that the U.S. Food and Drug Administration Psychopharmacologic Drugs Advisory Committee voted 12 to 1 that VIVITROL should be approved for the treatment of opioid dependence.


Structural Molecule Worsens Pneumonia

September 21, 2010 8:42 am | News | Comments

A structural molecule and the cellular pump that regulates its levels influence the severity of pneumonia and could provide new ways of treating the lung infection, which is a leading cause of hospitalization and death.


Marijauna-Like Chemical Controls Pain from Injury

September 21, 2010 8:40 am | News | Comments

American and Italian researchers have found that a novel drug allows anandamide – a marijuana-like chemical in the body – to effectively control pain at the site of an injury.



You may login with either your assigned username or your e-mail address.
The password field is case sensitive.